Project Grant R50CA315376
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $147K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
- The National Cancer Institute awarded Oregon Health & Science University $625,179 on March 26, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate direct and indirect MCL1 inhibitor therapies for lung metastasis in osteosarcoma. The research deploys a bioengineered bone and lung model with real-time cell tracking to establish MCL1's role in osteosarcoma lung metastasis and identify the most effective MCL1 inhibitors for eliminating metastases in engineered...
- The National Cancer Institute awarded Colorado State University's Sponsored Programs division a project grant of $1,267,523 on September 12, 2025, under the Cancer Treatment Research program (CFDA 93.395) to investigate focal adhesion kinase (FAK) inhibition as a dual-targeting strategy for osteosarcoma metastasis prevention. The research defines mechanisms by which FAK signaling in osteosarcoma tumor cells and lung fibroblasts shapes immune composition of the lung metastatic tumor...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $426,828 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research targeting epigenetic vulnerabilities in osteosarcoma to enhance immunotherapy. The funded work addresses immunotherapeutic resistance in osteosarcoma, the most common bone sarcoma in children, by identifying and targeting epigenetic modifiers that suppress tumor antigen presentation and immune activation....
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $164,000 on July 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize osteosarcoma-specific CD24 glycosylation profiles and facilitate development of glycoform-targeted therapeutic antibodies. The research addresses metastatic osteosarcoma, where approximately 40 percent of patients relapse with pulmonary metastatic disease despite aggressive treatment. CD24, a...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $608,558 to the Research Institute at Nationwide Children's Hospital on April 2, 2026, under the Cancer Biology Research program (CFDA 93.396). The grant funds research to genetically and metabolically define high-risk neuroblastoma and develop effective therapeutic strategies. The project establishes and characterizes clinically relevant immunocompetent mouse models of...
- The National Cancer Institute awarded Oregon Health & Science University $1,042,004 on March 26, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a microphysiological bone metastasis-on-a-chip platform that models prostate cancer metastasis into vascularized and innervated bone tissue. The research platform incorporates a mineralized, osteocyte-embedded bone matrix supporting active osteoclast and osteoblast remodeling, perfusable pericyte-supported vasculature to...
- The National Cancer Institute awarded the Research Institute At Nationwide Children's Hospital $639,295 on May 8, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the molecular mechanisms of altered DNA binding and chromatin regulation by FET::ETS oncogenes. The project, which runs through April 30, 2031, focuses on understanding how fusion oncoproteins—specifically EWSR1::FLI1, the oncogenic driver of Ewing sarcoma—acquire neomorphic functions through...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Oregon Health & Science University $657,007 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a multiscale approach to controlling cellular interactions in premalignant tissues. The project aims to use physical science methods to manipulate interactions between multiple cell types in precancerous tissues to restore normal tissue function. The recipient will...
- The National Cancer Institute awarded Rutgers The State University of New Jersey $550,084 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop oligosaccharyltransferase (OST) inhibitors for the treatment of osteosarcoma. The funded research targets OST catalytic subunit redundancy to overcome pharmacokinetic liabilities of current OST inhibitors and advance lead candidates toward translational studies. The project encompasses two primary aims: medicinal...